Adult T-cell leukemia/lymphoma incidence rate in French Guiana: a prospective cohort of women infected with HTLV-1.
Journal
Blood advances
ISSN: 2473-9537
Titre abrégé: Blood Adv
Pays: United States
ID NLM: 101698425
Informations de publication
Date de publication:
12 05 2020
12 05 2020
Historique:
received:
07
02
2020
accepted:
01
04
2020
entrez:
13
5
2020
pubmed:
13
5
2020
medline:
15
5
2021
Statut:
ppublish
Résumé
Adult T-cell leukemia/lymphoma (ATL) is an aggressive malignancy caused by the human T-cell leukemia virus type 1 (HTLV-1). The incidence of ATL among HTLV-1 carriers remains largely unknown in endemic countries other than Japan as very few prospective studies have been performed. We assessed the ATL incidence rate among HTLV-1 infected women in a prospective cohort in French Guiana. This is the first prospective study to assess the ATL incidence rate in an area of South America where HTLV-1 prevalence is high. Patients were enrolled between 1991 and 2005, and follow-up continued until April 2018. In the general hospital in Saint-Laurent-du-Maroni, 307 pregnant women were diagnosed with HTLV-1 infection, and 268 of them were observed for a median of 16.7 years. During follow-up, 9 ATL incident cases occurred resulting in an ATL incidence rate of 2.03 per 1000 HTLV-1 carrier-years (95% confidence interval, 0.93-3.85 per 1000 HTLV-1 carrier-years). The median age at diagnosis was 47.4 years, and median survival from diagnosis was low at 3.5 months. The ATL incidence rate was elevated for a study population consisting mostly of young people, which could either be a general feature in South America or could be specific to the Noir Marron population that constituted most of the cohort.
Identifiants
pubmed: 32396612
pii: S2473-9529(20)31336-7
doi: 10.1182/bloodadvances.2020001628
pmc: PMC7218432
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2044-2048Informations de copyright
© 2020 by The American Society of Hematology.
Références
J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Feb 1;17(2):167-70
pubmed: 9473019
N Engl J Med. 1974 Mar 7;290(10):572-3
pubmed: 4544052
Int J Cancer. 1998 May 4;76(3):331-6
pubmed: 9579568
Int J Cancer. 1995 Mar 16;60(6):773-6
pubmed: 7896443
Ned Tijdschr Geneeskd. 1996 Aug 17;140(33):1689-92
pubmed: 8830293
Cancer Causes Control. 2003 Nov;14(9):889-96
pubmed: 14682446
Int J STD AIDS. 2017 Mar;28(3):217-228
pubmed: 28178905
Br J Haematol. 1991 Nov;79(3):428-37
pubmed: 1751370
J Acquir Immune Defic Syndr Hum Retrovirol. 1995 Apr 1;8(4):420-5
pubmed: 7882109
Am J Hum Genet. 2017 Nov 2;101(5):725-736
pubmed: 29100086
J Acquir Immune Defic Syndr (1988). 1990;3(11):1096-101
pubmed: 2213510
Int J Cancer. 2001 Feb 15;91(4):497-9
pubmed: 11251972
Front Microbiol. 2012 Nov 15;3:388
pubmed: 23162541
Front Microbiol. 2012 Sep 10;3:322
pubmed: 22973265
Arch Intern Med. 1999 Jul 12;159(13):1485-91
pubmed: 10399901
Br J Haematol. 2019 Feb;184(4):688-689
pubmed: 29527675
Ann Intern Med. 1987 Mar;106(3):361-8
pubmed: 2880536
Int J Infect Dis. 2013 Nov;17(11):e1022-4
pubmed: 23642569
BMC Evol Biol. 2010 Oct 19;10:314
pubmed: 20958967
Int J Cancer. 1989 Feb 15;43(2):250-3
pubmed: 2917802
Int J Cancer. 2000 Aug 15;87(4):534-8
pubmed: 10918194
J Clin Microbiol. 2004 May;42(5):2020-6
pubmed: 15131164
Lancet Infect Dis. 2020 Jan;20(1):133-143
pubmed: 31648940
Cancer Sci. 2017 Dec;108(12):2478-2486
pubmed: 28905463
Blood. 2010 Aug 26;116(8):1211-9
pubmed: 20448111
Cancer Sci. 2006 Jun;97(6):535-9
pubmed: 16734733
Am J Trop Med Hyg. 2005 Sep;73(3):560-5
pubmed: 16172481